8-K Announcements
6Material company update
Dec 29, 2025·SEC
Material company update
Dec 8, 2025·SEC
Material company update
Nov 25, 2025·SEC
Clearside Biomedical, Inc.(CLSD)Earnings, Financials & Key Ratios
CLSD•NASDAQ
$0.41
Price updated Jun 20, 2026
AboutClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Show more
- Revenue$2M-79.8%
- EBITDA-$29M-15.7%
- Net Income-$34M-5.7%
- EPS (Diluted)-7.05+11.3%
- Gross Margin91.05%-4.8%
- EBITDA Margin-1722.12%-471.7%
- Operating Margin-1735.7%-474.7%
- Net Margin-2064.42%-422.8%
CLSD Price & Volume
Clearside Biomedical, Inc. (CLSD) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Pipeline Viability
Investment Thesis • Updated 2025Q3
VerdictNegative: The company's precarious liquidity position
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
Key Thesis Takeaways
- Clearside Biomedical faces a precarious financial outlook characterized by a heavy reliance on volatile milestone payments and a rapidly depleting cash reserve.
- While the company continues to prioritize R&D investment, the lack of consistent commercial revenue from its XIPERE product line leaves the firm vulnerable to significant liquidity risks.
- Investors should monitor the company's ability to secure additional capital, as the current trajectory of negative equity and operating losses suggests a high probability of future dilution or solvency challenges.
Verdict Logic
highlighted by a cash balance that has plummeted from $35.4 million in 2024Q1 to $6.8 million in 2025Q3, presents an unsustainable risk profile for long-term investors.
CLSD Growth Metrics
Clearside Biomedical, Inc. (CLSD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-5.2%
3 Years-61.68%
TTM-56.78%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.45%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.94%
Return on Capital
10 Years-111.15%
5 Years-81.36%
3 Years-87.37%
Last Year-121.51%
Peers Comparison
Key metrics vs top competitors for Clearside Biomedical, Inc. (CLSD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.41 | $2.15M | -0.06 | -79.77% | -2064.42% | — | — | |
| $9.66 | $2.12B | -6.80 | -18.67% | -558.24% | -64.55% | — | |
| $4.36 | $96.26M | -0.66 | -72.22% | — | — | — | |
| $3.99 | $435.68M | -1.99 | — | — | -70.79% | — | |
| $11.47 | $962.85M | -3.39 | — | — | -128.57% | — | |
| $17.32 | $1.97B | -14.20 | 8.28% | -25.66% | -50.82% | — |
Compare CLSD vs Peers
Clearside Biomedical, Inc. (CLSD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLSD SEC Filings & Documents
Clearside Biomedical, Inc. (CLSD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CLSD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CLSD Frequently Asked Questions
Clearside Biomedical, Inc. (CLSD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Clearside Biomedical, Inc.'s revenue?
Clearside Biomedical, Inc. (CLSD) reported $3.3M in revenue for fiscal year 2024.
How fast is Clearside Biomedical, Inc. growing?
Clearside Biomedical, Inc. (CLSD) saw revenue decline by 79.8% over the past year.
Is CLSD profitable?
Clearside Biomedical, Inc. (CLSD) reported a net loss of $26.0M for fiscal year 2024.
Dividend & Returns
What is Clearside Biomedical, Inc.'s free cash flow?
Clearside Biomedical, Inc. (CLSD) had negative free cash flow of $21.7M in fiscal year 2024, likely due to heavy capital investments.